Ebrahim Versi, MD in Eden Prairie, MN - Obstetrics & Gynecology

Ebrahim Versi, MD is a Obstetrics & Gynecology - Gynecologic Oncology physician based in Eden Prairie, Minnesota. Ebrahim Versi is licensed to practice in Massachusetts (license number 81853) and his current practice location is 6585 City West Pkwy, Eden Prairie, Minnesota. He can be reached at his office (for appointments etc.) via phone at (908) 698-2390.

NPI number for Ebrahim Versi is 1184732406 and his current mailing address is 11 Sheephill Dr, Gladstone, New Jersey. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1184732406.

Contact Information

	Ebrahim Versi, MD
	6585 City West Pkwy, Eden Prairie, MN 55344-3248
	(908) 698-2390
	Not Available

Physician's Profile

Full Name	Ebrahim Versi
Gender	Male
Speciality	Obstetrics & Gynecology - Gynecologic Oncology
Location	6585 City West Pkwy, Eden Prairie, Minnesota
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1184732406
Provider Enumeration Date: 08/27/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Ebrahim Versi such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1184732406	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207VX0201X	Obstetrics & Gynecology - Gynecologic Oncology	81853 (Massachusetts)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Ebrahim Versi is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Ebrahim Versi, MD 11 Sheephill Dr, Gladstone, NJ 07934-2131 Ph: (908) 698-2390	Ebrahim Versi, MD 6585 City West Pkwy, Eden Prairie, MN 55344-3248 Ph: (908) 698-2390

News Archive

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.

Study searches for the origins of depressive symptoms in Huntington's disease

About 40% of the affected patients with Huntington's disease -a neurodegenerative pathology- show depression symptoms, even in early stages before the apparition of the typical motor symptoms of the disease.

Women who smoke during pregnancy risk having aggressive kids

While previous studies have shown that smoking during gestation causes low birth weight, this research shows mothers who light up during pregnancy can predispose their offspring to an additional risk: violent behaviour.

Additional MRI scan during pregnancy could help accurately detect foetal abnormalities

An additional MRI scan during pregnancy could help to more accurately detect foetal abnormalities and give more certainty for parents whose 20-week ultrasound scan showed a potential problem, according to new research by scientists at the University of Sheffield.

Scientists identify new targets to develop treatment for HD

Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington's disease. These enzymes, matrix metalloproteinases, provide new targets for drug therapies for the disease - targets that have already been shown to respond to cancer drugs currently in clinical development.

Ebrahim Versi, MD - Obstetrics & Gynecology in Eden Prairie, MN